165 related articles for article (PubMed ID: 32719981)
1. Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis.
Suzuki T; Harada A; Shimada H; Hosoi T; Kawata Y; Inoue T; Saito H
J Bone Miner Metab; 2020 Nov; 38(6):859-867. PubMed ID: 32719981
[TBL] [Abstract][Full Text] [Related]
2. Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study.
Saito K; Miyakoshi N; Matsunaga T; Hongo M; Kasukawa Y; Shimada Y
J Bone Miner Metab; 2016 Sep; 34(5):547-54. PubMed ID: 26209166
[TBL] [Abstract][Full Text] [Related]
3. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
Sugimoto M; Futaki N; Harada M; Kaku S
Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
5. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Zhang ZL; Liao EY; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; De Peng Y; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L; Santora AC
Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
7. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
9. Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Aging Clin Exp Res; 2005 Apr; 17(2):157-63. PubMed ID: 15977465
[TBL] [Abstract][Full Text] [Related]
10. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
Devogelaer JP; Broll H; Correa-Rotter R; Cumming DC; De Deuxchaisnes CN; Geusens P; Hosking D; Jaeger P; Kaufman JM; Leite M; Leon J; Liberman U; Menkes CJ; Meunier PJ; Reid I; Rodriguez J; Romanowicz A; Seeman E; Vermeulen A; Hirsch LJ; Lombardi A; Plezia K; Santora AC; Yates AJ; Yuan W
Bone; 1996 Feb; 18(2):141-50. PubMed ID: 8833208
[TBL] [Abstract][Full Text] [Related]
11. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
12. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
[TBL] [Abstract][Full Text] [Related]
13. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
14. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
BMC Musculoskelet Disord; 2018 Jul; 19(1):210. PubMed ID: 29970059
[TBL] [Abstract][Full Text] [Related]
15. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
16. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
[TBL] [Abstract][Full Text] [Related]
17. Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors.
Waltman NL; Twiss JJ; Ott CD; Gross GJ; Lindsey AM; Moore TE; Berg K
J Nurs Scholarsh; 2003; 35(4):333-8. PubMed ID: 14735675
[TBL] [Abstract][Full Text] [Related]
18. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial.
Kim KJ; Min YK; Koh JM; Chung YS; Kim KM; Byun DW; Kim IJ; Kim M; Kim SS; Min KW; Han KO; Park HM; Shin CS; Choi SH; Park JS; Chung DJ; Mok JO; Baek HS; Moon SH; Kim YS; Lim SK;
Yonsei Med J; 2014 May; 55(3):715-24. PubMed ID: 24719139
[TBL] [Abstract][Full Text] [Related]
20. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
